

What is claimed is:

1. A compound selected from the group consisting of:

7-chloro-3-[(2-chlorophenyl)amino]-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

5 7-chloro-5-(methoxy)-2*H*-1,2,4-benzothiadiazin-3(4*H*)-one 1,1-dioxide

7-chloro-*N*-(2-chlorophenyl)-5-(methoxy)-4*H*-1,2,4-benzothiadiazin-3-amine 1,1-dioxide

7-chloro-3-[(2-chlorophenyl)amino]-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

7-chloro-3-(cyclopentylamino)-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

10 7-chloro-3-[(2,3-dichlorophenyl)amino]-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

3-[(2-chlorophenyl)amino]-7-nitro-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

N-(2-chlorophenyl)-5-(methoxy)-7-nitro-4*H*-1,2,4-benzothiadiazin-3-amine 1,1-dioxide

3-[(2-chlorophenyl)amino]-7-nitro-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

15 3-[(2-bromophenyl)amino]-7-nitro-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

7-nitro-3-[[2-(phenyloxy)phenyl]amino]-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

3-[(2-chloro-3-fluorophenyl)amino]-7-nitro-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

3-[(2-chlorophenyl)amino]-4*H*-1,2,4-benzothiadiazin-5-ol 1,1-dioxide

N-(2-chlorophenyl)-5-(methoxy)-4*H*-1,2,4-benzothiadiazin-3-amine 1,1-dioxide

20

2. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier or diluent.

3. A method of treating a chemokine mediated disease, wherein the chemokine binds
25 to an IL-8 a or b receptor in a mammal, which method comprises administering to said mammal an effective amount of a compound according to Claim 1.

4. The method according to Claim 3 wherein the mammal is afflicted with a chemokine mediated disease selected from the group consisting of psoriasis, atopic
30 dermatitis, arthritis (either osteo- or rheumatoid), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis,

toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction, alzheimers disease, allograft rejections, malaria, restinosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis, viral diseases such as rhinovirus and undesired hematopoietic stem cell release.

5